BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Brixko C, Laukens P, Orlent H, Bilaey P, De Smet F, Hellemans G, Muyldermans G, Van Baelen L, Hens N, Van Vlierberghe H, Robaeys G. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis 2021;21:708. [PMID: 34315415 DOI: 10.1186/s12879-021-06405-z] [Reference Citation Analysis]
2 Busschots D, Kremer C, Koc ÖM, Heyens L, Bielen R, Apers L, Florence E, Messiaen P, Van Laethem K, Van Wijngaerden E, Nevens F, Hens N, Robaeys G. The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination. Int J Infect Dis 2021;105:217-23. [PMID: 33610786 DOI: 10.1016/j.ijid.2021.02.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Reference Citation Analysis]
4 Krumb E, Lambert C, Horsmans Y, Hermans C. Diagnosis of hepatitis C-related liver disease in patients with mild hemophilia. Eur J Intern Med 2021;91:102-3. [PMID: 34103222 DOI: 10.1016/j.ejim.2021.05.033] [Reference Citation Analysis]
5 Han R, Liang S, François C, Aballea S, Clay E, Toumi M. Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. J Mark Access Health Policy 2021;9:1887664. [PMID: 33828822 DOI: 10.1080/20016689.2021.1887664] [Reference Citation Analysis]
6 Chan H, Hassali MA, Md Said R, Abu Hassan MR. Treatment Coverage and Drug Expenditure in Hepatitis C Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through Government-led Initiatives. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.107372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Abdelaziz H, Omar H, Khalil M, Cordie A, Mohamed R, AbdAllah M, Abdel Maksoud MH, El Garhy N, Ali L, El Serafy M, Esmat G, Doss W. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34751609 DOI: 10.1080/14787210.2022.2004117] [Reference Citation Analysis]
8 Busschots D, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Janssens F, Van den Bergh L, Van Lint P, Bruckers L, Nevens F, Robaeys G. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. BMC Public Health 2021;21:1574. [PMID: 34416867 DOI: 10.1186/s12889-021-11608-9] [Reference Citation Analysis]
9 Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, Hickman M, Hutchinson S, Dillon JF. Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther 2021. [PMID: 34877667 DOI: 10.1111/apt.16728] [Reference Citation Analysis]
10 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Kowalik-Mikołajewska B, Marczyńska M. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klin Padiatr 2020. [PMID: 33339066 DOI: 10.1055/a-1304-3542] [Reference Citation Analysis]